However, the risk implication of RAD51B variants seems to be an exception, which has been robustly replicated in different studies on breast cancer 5, 6, 7, 8, nasopharyngeal carcinoma 9, glioma 10, and cutaneous melanoma 11, suggesting the significant role of RAD51B variants in cancer risk. This evidence concerns the gene RAD51B and central nervous system cancer.